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AbstrACt 
Introduction Diabetic macular oedema (DMO) and 
proliferative diabetic retinopathy (PDR) are the major 
causes of sight loss in people with diabetes. Due to the 
increased prevalence of diabetes, the workload related 
to these complications is increasing making it difficult for 
Hospital Eye Services (HSE) to meet demands.
Methods and analysis Effectiveness of Multimodal 
imaging for the Evaluation of Retinal oedema And 
new vesseLs in Diabetic retinopathy (EMERALD) is a 
prospective, case-referent, cross-sectional diagnostic 
study. It aims at determining the diagnostic performance, 
cost-effectiveness and acceptability of a new form of 
surveillance for people with stable DMO and/or PDR, 
which entails multimodal imaging and image review by 
an ophthalmic grader, using the current standard of care 
(evaluation of patients in clinic by an ophthalmologist) 
as the reference standard. If safe, cost-effective and 
acceptable, this pathway could help HES by freeing 
ophthalmologist time. The primary outcome of EMERALD 
is sensitivity of the new surveillance pathway in detecting 
active DMO/PDR. Secondary outcomes include specificity, 
agreement between new and the standard care pathway, 
positive and negative likelihood ratios, cost-effectiveness, 
acceptability, proportion of patients requiring subsequent 
full clinical assessment, unable to undergo imaging, with 
inadequate quality images or indeterminate findings.
Ethics and dissemination Ethical approval was 
obtained for this study from the Office for Research Ethics 
Committees Northern Ireland (reference 17/NI/0124). 
Study results will be published as a Health Technology 
Assessment monograph, in peer-reviewed national 
and international journals and presented at national/
international conferences and to patient groups.
trial registration number NCT03490318 and 
ISRCTN:10856638.
IntroduCtIon
Diabetic retinopathy (DR) is the most 
common microvascular complication of 
diabetes and a leading cause of visual loss 
among individuals of working age.1 Patients 
with DR may lose sight as a result of the 
development of diabetic macular oedema 
(DMO) and/or proliferative diabetic reti-
nopathy (PDR), the major complications of 
DR. In the former, fluid accumulates in the 
central part of the retina, the macula, which 
is responsible for detailed central vision. In 
the latter, abnormal new blood vessels (‘new 
vessels’) grow on the optic nerve head or 
on the surface of the retina and towards the 
inside of the eye (the vitreous cavity) leading 
to sight loss from haemorrhaging and/or 
traction on the retina with subsequent retinal 
detachment. Due to the increasing numbers 
of people with diabetes, it is expected that the 
burden of DR will continue to rise. Indeed, it 
has been estimated that the worldwide preva-
lence of DR will increase from 126.6 million 
in 2010 to 191 million by 2030.2 
The prevalence of DMO in England was 
estimated to be 7% of the total diabetic popu-
lation in 2010.3 A very similar estimate of the 
prevalence was found in an individual partici-
pant data meta-analysis, which included 22 896 
individuals from 35 studies, conducted in Asia, 
strengths and limitations of this study
 ► Prospective, multicentre study.
 ► Masking of graders to results of the reference stan-
dard and masking of ophthalmologists to results of 
the grader’s pathway.
 ► Evaluation of the acceptability of the new pathway to 
patients and health professionals.
 ► Early involvement in all aspects of the study of pa-
tients and public.
 ► Lack of fluorescein angiography to confirm active 
proliferative diabetic retinopathy.
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Australia, Europe and the USA, which provided an overall 
age-standardised prevalence of DMO of 6.8%.4 Based on 
this published prevalence of DMO and considering the 
prevalence of diabetes in the UK,5 it can be estimated that 
there are 280 000 people in the UK affected by DMO. In 
the UK, patients with DMO are treated with focal or grid 
macular laser (when the central retinal thickness (CRT), 
measured by means of spectral domain optical coherence 
tomography (SD-OCT), is <400 microns), which is deliv-
ered in a single session, or with injections into the eye of 
antivascular endothelial growth factor (anti-VEGF) ther-
apies, currently in the National Health Service (NHS) 
ranibizumab (Lucentis) and aflibercept (Eylea) (when 
the CRT measured by SD-OCT is >400 microns).6 7 Intra-
ocular steroids are also available for patients who do not 
respond to the above therapies and are pseudophakic (ie, 
have had their cataracts removed).8 Once treated, long-
term follow-up is required to determine whether DMO 
recurs. Typically, patients are followed every 3–4 months 
following laser treatment for DMO or monthly initially 
and then every 1–3 months thereafter following treat-
ment with anti-VEGFs.9 Follow-up continues for the rest 
of the patient’s life.
The estimated prevalence of PDR in the individual 
participant data meta-analysis referred to above4 was 
6.96%; based on the prevalence of diabetes in the UK,5 
there are ~278 400 people in the UK affected by PDR. 
At present in the UK, patients with PDR are treated with 
panretinal laser photocoagulation (PRP), which is deliv-
ered most often in two to three sessions. Once treatment 
is completed, patients are followed at 4–6 months inter-
vals for their lifetime to determine whether reactivation 
occurs, as new vessels in PDR could come back and trac-
tional retinal detachment can still ensue.9 A high propor-
tion of patients with DR followed in Hospital Eye Services 
(HES) have treated and inactive PDR.10
Currently in the NHS ophthalmologists with exper-
tise in retinal diseases assess patients during follow-up 
visits. At each visit, patients with DMO are evaluated with 
a visual acuity test, most often undertaken by a nurse; 
SD-OCT, obtained by a photographer and interpreted 
by the ophthalmologist, and slit-lamp biomicroscopy, 
undertaken by an ophthalmologist, who then deter-
mines whether DMO is present or absent. SD-OCT is a 
non-invasive, user-friendly and safe imaging technique 
that obtains scans of the back of the eye. SD-OCT allows 
measurement of the CRT (which is often increased when 
DMO is present) and visualising fluid in the retina which 
is the hallmark of DMO. SD-OCT has been extensively 
used in clinical trials and clinical practice to determine 
the presence of DMO, select treatment and monitor the 
response to treatment.11–17 In the follow-up of patients 
with PDR, ophthalmologists typically examine the patient 
by slit-lamp biomicroscopy. Photographs are not routinely 
obtained in clinic to determine whether or not active 
PDR is present. Standard cameras are not able to image 
the whole retina. It is possible, however, to obtain several 
images to capture the appearance of the centre, superior 
and inferior parts of the retina; the retinal periphery 
cannot be imaged with standard cameras. In recent 
years, new ultra-wide field imaging has become available, 
allowing imaging of the entire retina. This technology 
may be, thus, preferable, and it may be easier for patients 
and reduce the time required to obtain images.
Given the high number of people with DMO and PDR, 
the need for patients to be seen at short follow-up inter-
vals, the need for frequent treatments and the require-
ment for long-term follow-up, there is a very large 
workload in HES related to DMO/PDR. This is making it 
difficult for the NHS to cope with the demand, in partic-
ular, due to shortage of ophthalmologists. This is only 
expected to get worse given the increasing prevalence 
of diabetes. Identifying new ways of increasing the NHS 
capacity and efficiency without compromising quality of 
care would greatly benefit the NHS.
The purpose of EMERALD is to determine whether 
successfully treated patients with DMO/PDR could 
be followed without a face-to-face examination by an 
ophthalmologist. EMERALD will evaluate a new care 
pathway, which will include multimodal retinal imaging 
and separate image assessment by trained ophthalmic 
graders. This new pathway will be compared with the 
current standard care pathway which is, for DMO, having 
an ophthalmologist evaluating patients in clinic by slit-
lamp biomicroscopy and with access to SD-OCT images 
and for PDR evaluating patients in clinic by slit-lamp 
biomicroscopy. EMERALD will determine how accurate 
the new pathway is at determining which patients have 
active or inactive disease when compared with the stan-
dard of care and its costs and acceptability by patients and 
health professionals.
MEthods And AnAlysIs
study design and setting
Prospective, diagnostic study of patients with DMO, PDR 
or both, who had been previously successfully treated 
and who, at the time of enrolment in the study, may have 
active or inactive disease (both are required to evaluate 
the diagnostic performance of the new pathway).
EMERALD has a case-referent cross-sectional diag-
nostic study design with both sampling (selection) of 
patients and data collection carried out prospectively.18 
This approach provides both a cost-efficient study design 
and low risk of bias in terms of diagnostic accuracy.19
EMERALD is set within specialised HES in the UK. All 
participating centres have extensive experience with the 
management of DMO and PDR.
Patient and public involvement
A patient and public involvement (PPI) group was estab-
lished early on in the study, at the stage of trial concep-
tion. The PPI group confirmed the research question 
was important to patients, the tests to be undertaken for 
the purpose of the study were adequate and feasible to 
be performed in the clinical setting and the outcomes 
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measured relevant to them. The PPI group provided 
essential input to the patient-related materials produced 
for the study, including the patient information sheet and 
consent form. Furthermore, patients' views on the path-
ways of care investigated will be evaluated specifically in 
the study (see 'Focus groups discussions: assessment of 
acceptability of the new care pathway' section). The PPI 
group will be actively involved in the dissemination of the 
results. Patients were not involved in the recruitment of 
participants in the study.
Participants: eligibility criteria
Inclusion criteria
Adults (18 years of age or older) with type 1 or 2 diabetes 
with previously successfully treated DMO and/or PDR in 
one or both eyes and in whom, at the time of enrolment 
in the study, DMO and/or PDR may be active or inactive. 
Patients can be recruited only once.
Active DMO is defined as CRT of >300 microns and/or 
presence of intraretinal/subretinal fluid on SD-OCT due 
to DMO.
Inactive DMO is defined as no intraretinal/subretinal 
fluid.
Active PDR is defined by the presence of subhyaloid/
vitreous haemorrhage and/or active new vessels (new 
vessels with lack of fibrosis on them).
Inactive PDR is defined by the lack of preretinal/
vitreous haemorrhage and lack of active new vessels.
Exclusion criteria
1. Unable to provide informed consent.
2. Patients who do not read, speak or understand English.
outcome measures
Primary outcome
 ► Sensitivity of the new pathway (ophthalmic grader 
pathway) in detecting active DMO/PDR, using the 
standard care pathway as the reference standard.
Secondary outcomes
 ► Specificity, concordance (agreement) between 
new pathway (ophthalmic grader pathway) and the 
standard care pathway, positive and negative likeli-
hood ratios.
 ► Cost-effectiveness.
 ► Acceptability.
 ► Proportion of patients requiring subsequent full clin-
ical assessment.
 ► Proportions of patients unable to undergo imaging, 
with inadequate quality images or indeterminate 
findings.
study procedures and schedule of assessments
Ophthalmic grader pathway and standard care pathway
In EMERALD, a new clinical care pathway (figure 1), 
the ophthalmic grader pathway, will be evaluated and 
compared with the current standard of care.
If this new pathway were to be used in clinical practice, 
patients would undergo multimodal retinal imaging with 
subsequent review by trained ophthalmic graders. If active 
disease were to be detected or if the ophthalmic grader 
were to be uncertain as to whether or not there was active 
DMO/PDR present, the patient would be referred to an 
ophthalmologist for a full assessment. If the patient were 
to be stable (ie, inactive DMO/PDR), the patient would 
remain under this model of surveillance with a predeter-
mined interval.
For the purpose of EMERALD, all patients will go 
through the standard care pathway which is: 1) for DMO: 
ophthalmologist evaluating patients in clinic by slit-lamp 
biomicroscopy and with access to SD-OCT images, which 
are routinely obtained for the evaluation of DMO in 
clinic; 2) for PDR: ophthalmologists evaluating patients 
in clinic by slit-lamp biomicroscopy.
Selection of ophthalmic graders and training
Currently, ophthalmic photographers/imaging techni-
cians obtain images and interpret them routinely, but 
make no decisions on the care of patients. In ophthalmic 
services, there are also ophthalmic graders that have been 
trained to interpret findings on fundus images for the 
purpose of undertaking DR screening.
For EMERALD, the ophthalmic graders at each partici-
pating site will be selected as follows. First, local principal 
investigators (PIs) would provide names of individuals 
they believe have experience obtaining and/or grading 
images of patients with DMO and PDR; these individ-
uals would be also confirming their interest and willing-
ness to participate in EMERALD. It is possible that some 
ophthalmic graders selected for EMERALD will be already 
involved in the grading of images for DR screening.
Graders identified by the PIs will be asked to fill out 
questionnaires detailing their experience imaging/
grading DMO/PDR, recognising features of DMO/
PDR and whether they feel confident identifying DMO 
on SD-OCT and new vessels on fundus images. Graders 
stating they do not have experience imaging/grading 
DMO/PDR and/or those stating they could not recog-
nise features of DMO/PDR will not be invited to take part 
in EMERALD as graders.
Formal training, during a training meeting(s) in which 
features of active/inactive DMO/PDR will be reviewed 
and discussed and where extensive clinical examples 
will be presented, will be provided to all EMERALD 
Figure 1 Summary of ophthalmic grader pathway. DMO, 
diabetic macular oedema; PDR, proliferative diabetic 
retinopathy; SD-OCT, spectral domain optical coherence 
tomography. 
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ophthalmic graders prior to the initiation of the study, as 
described in the EMERALD Study Manual.
To ensure graders selected will be in a position to under-
take the task of grading images, all potential graders will 
be required to take a test involving the reading of OCTs 
and fundus images. Only those graders who reach a 
minimum of 80% of correct answers to detect presence 
of DMO or active PDR, when present, will be invited 
to act as graders. Graders will be allowed to undergo 
further training and take the test a second time but if the 
minimum of correct answers is not reached they will not 
be able to act as graders.
A web-based teaching module with examples of DMO/
PDR will be prepared so that graders can access it to 
consolidate their knowledge. Clear guidelines on when 
patients would need to be referred for an assessment by 
an ophthalmologist will be also given.
schedule of assessments for EMErAld
Patient flow and procedures undertaken in EMERALD 
have been summarised in figure 2.
Written informed consent will be obtained by ophthal-
mologists/deputes from all participants prior to any study 
procedures being undertaken.
The following information obtained during the stan-
dard care pathway will be recorded in the case report 
forms (CRFs):
 ► Medical and ophthalmic history.
 ► Best-corrected visual acuity.
 ► Whether there was active or inactive DMO/PDR and 
whether or not there were features that could make 
imaging difficult (eg, small pupil).
 ► Details on presence/absence and location of active/
inactive new vessels in the disc and elsewhere in the 
retina and/or preretinal haemorrhage/vitreous 
haemorrhage.
 ► Presence of any other co-existent eye disease noted.
 ► Information on the proposed plan for the patient.
Patients will undergo ETDRS 7-field and ultra-wide 
field imaging, obtained following the guidelines set in the 
EMERALD Study Manual and will complete EQ-5D 5 L, 
NEI VFQ-25 and VisQoL questionnaires.
Patients willing to participate in the Focus Group 
Discussions will be consented; a group of them will be 
contacted at a later date for this purpose (see below).
Fundus photographs and SD-OCTs will be anonymised 
and transferred to Queen's University Belfast reading 
centre where they will be uploaded in an electronic 
website developed for the study; these anonymised images 
will be then made accessible to the ophthalmic graders 
(and ophthalmologists determining the ‘enhanced refer-
ence standard’ for PDR, see below) for the purpose of 
grading.
Ophthalmic graders will determine (and record in the 
appropriate CRF):
 ► Whether there is active/inactive DMO/PDR (or if 
unsure);
 ► Location of new vessels;
 ► Whether patient could continue review in the 
ophthalmic grader pathway or requires assessment by 
an ophthalmologist and the reasons why.
Enhanced reference standard
The reference standard for PDR (ophthalmologist eval-
uating patients in clinic by slit-lamp biomicroscopy) will 
be used for the primary analysis. The reference standard 
for PDR, however, could potentially be improved. There 
is a possibility that new vessels (indicative of PDR) may 
not be seen by the ophthalmologist on slit-lamp biomi-
croscopy but could be detected in a fundus photograph. 
In order to determine the impact of this potential event, 
EMERALD will also evaluate an alternative ‘enhanced’ 
reference standard which will consist of the ophthal-
mologist assessment supplemented by the evaluation 
of the fundus images (7-field ETDRS and ultra-wide 
field fundus images) done by an ophthalmologist. This 
reading by the ophthalmologist of the fundus images 
will be done only after the reference standard has been 
set, to ensure it will not affect or influence the refer-
ence standard. If either, slit-lamp biomicroscopy, 7-field 
ETDRS or ultra-wide angle fundus images detect active 
PDR, the patient will be considered to have ‘active’ PDR 
under this ‘enhanced’ reference standard. This informa-
tion will be recorded in the appropriate CRF. The PDR 
status based on the enhanced reference standard will be 
used in a sensitivity analysis of the new pathway’s diag-
nostic accuracy.
Figure 2 Study flow chart. DMO, diabetic macular oedema; 
ETDRS, early treatment diabetic retinopaty study; PDR, 
proliferative diabetic retinopathy; OCT, optical coherence 
tomography. 
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Masking
Ophthalmic graders will be masked to the reference stan-
dard; to ensure this, they will not interpret images from 
patients recruited at their own centre and will not have 
access to results of the reference standard. They will not 
read 7-field ETDRS and wide-angle fundus images or 
SD-OCTs of the same eye either, to ensure their reading of 
one imaging technology will not influence their reading 
of the other.
Ophthalmologists doing the standard of care evalua-
tion will also be masked to the findings/decisions made 
by the ophthalmic graders (who will be reviewing the 
images at a later date).
Ophthalmologists determining the ‘enhanced’ refer-
ence standard will be masked in the same manner as the 
ophthalmic graders.
Patients will also be masked to findings/decisions made 
by the ophthalmic graders (these will not be available at 
the time of the study’s clinical visit).
Data collection and quality checks
CRFs will be used to collect data. Monitoring during the 
study will check the accuracy of entries on CRF’s against 
source documents, adherence to protocol, procedures 
and to the International Conference of Harmonisa-
tion Good Clinical Practice guidelines and regulatory 
requirements. Monitoring visits will be undertaken by a 
monitor from the Northern Ireland Clinical Trials Unit 
(NICTU). To ensure accurate, complete and reliable data 
are collected, the Chief Investigator and the NICTU will 
provide training to site staff.
Study data will be entered onto a web-based Clinical 
Trial Database by NICTU personnel and processed elec-
tronically. Data quality control checks will be carried 
out by a data manager to ensure accuracy; data errors 
will be documented in Quality Control Reports with 
corrective actions implemented. Data validation will be 
implemented and discrepancy reports will be generated 
following data entry to identify discrepancies such as out 
of range, inconsistencies or protocol deviations based on 
data validation checks programmed in the clinical trial 
database.
Sample size
The sample size was determined on the basis of setting 
a target of the number of reactivated (active) DMO and 
PDR patients, which would enable sensitivity to be tested 
against a prespecified target level of 80%.20 This level 
was considered the minimum acceptable level for the 
new pathway (ophthalmic grader pathway) to be clini-
cally viable. A lower specificity is considered acceptable 
and a target of 65% for specificity was used to confirm 
sufficiency of the sample size for assessing specificity. To 
detect the sensitivity of the new pathway (photographer/
imaging technician pathway) with 80% and 90% power 
(10% and 12% higher than the 80% minimal target set) 
would require 89 participants with each DMO/PDR who 
have reactivated (active DMO/PDR), with two-sided 5% 
significance level.21 Ninety-three participants who have 
not reactivated would enable a specificity 15% (10%) 
higher than the 65% target to be detected with 90% 
power. A 95% CI for photographer sensitivity and spec-
ificity would have a CI (Wilson method) with a width of 
10%–20% depending on the observed level.22 Allowing 
for 10% missing/indeterminate results, 104 individuals 
who have re-activated and 104 who have not, are required 
(208 for each, DMO and PDR) which leads to a need for 
a maximum of 416 participants in the study overall; some 
participants may have both DMO and PDR contributing 
to both DMO and PDR targets.
Data analysis plan
Outcomes for DMO and PDR will be assessed in two sepa-
rate analyses. Participants will be categorised as having 
active, inactive or no DMO/PDR according to the diag-
nosis established at the standard care pathway at the 
person level (ie, using data from both eyes where appro-
priate). Active and inactive DMO/PDR will be subcate-
gorised as previously successfully treated or not. Those 
which had previously successfully treated DMO/PDR 
constitute ‘eligible’ patients for the new pathway. This 
person-based assessment reflects the consequences of 
the clinical decision. The diagnostic performance of the 
new pathway will be quantified by assessing against the 
standard care pathway. Reflecting how the new pathway 
would function in practice, an ‘unsure’ classification or 
an ‘active’ classification will both require an examination 
by an ophthalmologist under the main analyses.
A number of sensitivity analyses will be carried out. 
These will include 1) an assessment of the impact of 
the ‘unsure’ ophthalmic classification on the diagnostic 
performance; 2) using the ophthalmologist’s decision 
to do further treatment rather than presence of active 
disease, given that in some patients with active disease the 
ophthalmologist may still consider observation if only very 
mild disease is present, 3) detection of disease in more 
severe cases (eg, high-risk PDR) and 4) the diagnostic 
performance within routine NHS clinics versus those 
set-up specifically for this research study. In addition, for 
PDR, a sensitivity analysis will assess the diagnostic perfor-
mance of the ophthalmic grader against the ‘enhanced’ 
reference standard.
The impact of using ultra-wide field or 7-field ETDRS 
images on the diagnostic performance of the new pathway 
will be assessed also under the principal analyses for PDR 
using both the standard and the enhanced reference 
standard.
Furthermore, secondary analyses will include 1) an 
evaluation based on eye level data, 2) an analysis that will 
include all patients (ie, including those with no disease), 
3) an assessment of using tests of both DMO and PDR with 
regard to an overall referral status and 4) the additional 
use of visual acuity as a proxy to detect active disease. We 
will quantify the proportion of patients identified by an 
ophthalmologist as having other eye comorbidities (eg, 
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epiretinal membrane, glaucoma, others) and will explore 
in relevant analyses their influence on the findings.
Sensitivity, specificity, positive and negative likelihood 
ratios will be calculated (with appropriate 95% CIs) for 
the alternative strategy using the current standard of care 
pathway findings as the reference standard. Agreement 
(concordance) between the new and current standard of 
care pathways will also be calculated (with 95% Wilson 
CI).22 The difference in sensitivity and specificity between 
ultra-wide field and 7-field ETDRS images assessed by the 
ophthalmic graders will be compared with corresponding 
95% CIs produced using Newcombe’s method for paired 
data.23
The proportion of patients requiring subsequent full 
clinical assessment or unable to undergo assessments, 
with inadequate quality images or indeterminate findings 
will be calculated for the alternative pathway with corre-
sponding CIs. All analyses will be carried out using STATA 
V.15.24
A detailed statistical analysis plan will be written by the 
trial statistician prior to the final analysis.
Health economic analysis
This analysis will take into account: 1) sensitivity and spec-
ificity of the ophthalmic grader pathway for both DMO 
and PDR; 2) whether this new pathway detects any PDR 
missed by the current standard of care and 3) relative 
costs.
In the ophthalmic grader pathway, patients will be in one 
of four groups depending on the decisions made by these 
staff after reading the images: 1) true negative—no treat-
ment required and patient will return for follow-up at the 
usual interval; 2) true positive—referred for ophthalmic 
assessment and treatment as required; 3) false negative—
patient who may come to harm by visual loss; 4) false posi-
tive—patient will be referred to the ophthalmologist but 
will not require treatment; these patients will not come to 
harm apart from possible anxiety and inconvenience, but 
will consume ophthalmologist time.
Scores obtained in the health-related quality of life 
questionnaire (EQ-5D-5L) and visual function question-
naires (NEI VFQ-25 and Vis-QoL) will provide utility 
data for different health states. Resource use data will be 
collected to explore the costs of delivering the standard 
care pathway and the ophthalmic grader pathway and to 
find the key cost drivers. This will mainly consist of staff 
costs. Costs of 7-field ETDRS images will be compared 
with those of ultra-wide angle imaging.
If the sensitivity and specificity of the new and standard 
pathways were exactly the same there would be no qual-
ity-adjusted life year (QALY) differences, although there 
might be some disutility from process changes (ie, if one 
pathway caused more anxiety than the other). The key 
gain would be ophthalmologist time freed for other activi-
ties. The real benefits might be reduction in waiting times 
and earlier treatment of other patients leading to QALY 
gains for them. Such benefits would be difficult to esti-
mate and the simplest measure would be ophthalmologist 
sessions/days released for other activities. However, we 
will identify ways in which time released would be used. 
An underlying assumption to be checked is that the cost 
of assessment by the ophthalmic graders is less than that 
of the ophthalmologists. Both pathways would require 
nurse or optometrist time for checking visual acuity, as 
done in routine clinical practice. The costs of the image-
based pathways will include both time for taking and 
reading images, using both conventional and ultra-wide 
field cameras. If there was marginal loss in sensitivity from 
the new pathway the consequences could be visual loss 
before next visit was due, or detection at next visit (with 
or without visual loss occurring) followed by possibly later 
than optimal treatment. Both could have disutilities.
It should be noted that assessment in clinical prac-
tice is repeated over time so active disease missed at one 
assessment might be picked up at the next. Given the 
cross-sectional design of EMERALD and the fact that all 
patients will undergo the standard care pathway, we will 
not be able to assess the disutility of any visual changes in 
patients recruited.
We will develop a Markov model using data from both 
this study (the EQ-5D 5 L data for different states) and 
published studies on progression, so analysis of the effect 
of a reduced sensitivity will include, for DMO and PDR 
separately: 1) probability of progression before next visit, 
2) probability that this would lead to irreversible visual 
loss and if so, how much; 3) if there was irreversible visual 
loss, the resulting disutility and QALY loss.
Specificity would be the determining factor in savings in 
ophthalmologist time: the poorer the specificity the lower 
the savings. In the PDR group, ultra-wide field imaging 
will be compared with both, standard care (ophthalmol-
ogist evaluating patients by slit-lamp biomicroscopy) and 
7-field ETDRS to assess the cost-effectiveness of this more 
recently introduced imaging modality.
Any future costs and benefits will be discounted at 
3.5%. NHS and personal social services perspective will 
be adopted. The model will be populated by cost, sensi-
tivity and specificity data from the study and by estimates 
of progression, effectiveness of treatment (prompt and 
delayed), quality of life and future costs from published 
literature and expert opinion. Results will be expressed 
as cost per QALY gained. Appropriate sensitivity analyses 
will be conducted to assess robustness of results. Proba-
bilistic sensitivity analyses will be undertaken to explore 
uncertainty in model parameters and to allow presenta-
tion of cost-effectiveness acceptability curves.
Focus groups discussions: assessment of acceptability of the new 
care pathway
The acceptability of the ophthalmic graders pathway will 
be evaluated through focus group discussions. Patients’ 
views on the acceptability of the proposed new pathway 
are essential if this were to be incorporated into clinical 
practice. Focus group discussions are particularly useful 
to help identify issues that resonate with lay people in 
matters of healthcare and have been widely used in 
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health services research; focus group discussions reach 
the parts that other methods cannot.25 Their use in this 
study will enable us to acquire data on a full range of 
issues—some of which are unlikely to have been antici-
pated by professionals. The sample frame is designed to 
include consenting participants drawn from different UK 
areas and different age groups. Group discussions will 
be facilitated by a trained researcher. Discussions will be 
audio-recorded and later transcribed for analysis.
Informed consent will be obtained from partici-
pants prior to the focus group discussions. Participants 
consenting to take part will be approached at a later date 
via letter/phone call to inform them about the date/loca-
tion/time of the meeting.
EMERALD will also examine the acceptability of the 
new pathway to health professionals. For this purpose, a 
small number of focus groups will be conducted involving 
photographer/imaging technicians/graders and ophthal-
mologists, all recruited from staff at participating sites.
The data from the focus groups will be analysed by the 
use of simple content analysis strategies. The focus of the 
analysis will be on ‘acceptability’ of the new alternative 
pathway and factors that might facilitate or impede such 
acceptability.26
EthICs And dIssEMInAtIon
The study is conducted in compliance with the protocol 
approved by the Research Ethics Committee (REC). 
Changes to the protocol may require REC approval prior 
to implementation. The NICTU in collaboration with the 
sponsor will submit all protocol modifications to the REC 
for review in accordance with the governing regulations.
Serious adverse events will be recorded and reported 
to the Office for Research Ethics Committees Northern 
Ireland.
In order to maintain participant’s confidentiality, a 
unique study identification number will be used for each 
participant. Study reports and communication regarding 
the study will identify the patients by their assigned 
unique trial identifier. Computers where information will 
be stored will be password protected.
A report containing the methodology and results of 
EMERALD will be published as a Health Technology 
Assessment monograph, freely accessible via the National 
Institute for Health Research (NIHR) Health Tech-
nology Assessment (HTA) website. The Royal College 
of Ophthalmologist will be contacted when the study is 
completed to allow the study findings to be incorporated 
in future diabetic retinopathy guidelines. Findings will be 
published in national/international peer-reviewed jour-
nals and presented at national/international meetings 
and patient groups.
Author affiliations
1Ophthalmology, Wellcome-Wolfson Institute for Experimental Medicine, Queen's 
University, Belfast, UK
2NDORMS, University of Oxford, Oxford, UK
3Gloucester Hospitals NHS Foundation Trust, Gloucester, UK
4The Division of Health Sciences, University of Warwick, Warwick, UK
5NDORMS, University of Oxford, Oxford, UK
6Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, 
UK
7The Manchester Academic Health Science Centre, University of Manchester, 
Manchester, UK
8Ophthalmology Department, Bristol Eye Hospital, Bristol, UK
9Ophthalmology, Royal Free Hospital NHS Foundation Trust, London, UK
10Ophthalmology, Bradford Royal Infirmary, Bradford, West Yorkshire, UK
11Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, Gloucestershire, UK
12NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, 
London
13Sunderland Eye Infirmary, Sunderland, UK
14Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
15Ophthalmology, Queen Margaret Hospital, Fife, UK
16Northern Ireland Clinical Trials Unit, Belfast, UK
17Queen's University Belfast, Belfast, UK
18Centre for Public Health, Queen's University, Belfast, UK
Acknowledgements The authors would like to thank the optometrists, 
research coordinators, research nurses, ophthalmic technicians and ophthalmic 
photographers for contributing to EMERALD at each of the participating sites. The 
authors would like to thank all the patients participating in EMERALD, those who 
were part of the PPI group and Diabetes UK, Northern Ireland. The authors would 
like to thank Janice Bailie, Alison Murphy and Lynn Murphy for their support, help 
and assistance with this diagnostic study and the UK Ophthalmology Clinical 
Research Network, Maurice O’Kane, Julie Silvestri, Jonathan Jackson, Paul Biagioni 
and the Ophthalmology Clinical Research Network for their support to EMERALD. 
Collaborators EMERALD Study Group: Ahmed Saad, James Cook University 
Hospital, South Tees Hospitals NHS Foundation Trust; Augusto Azuara-Blanco, 
Queen’s University and Royal Victoria Hospital, Belfast H&SC Trust; Caroline 
Styles, Queen’s Margaret Hospital, Fife; Christine McNally, Andrew Jackson and 
Rachael Rice, Northern Ireland Clinical Trials Unit; Clare Bailey, Bristol Eye Hospital, 
University Hospitals Bristol NHS Foundation Trust; Danny McAuley, Queen’s 
University and Royal Victoria Hospital, Belfast H&SC Trust; David H Steel, Sunderland 
Eye Infirmary, City Hospitals Sunderland NHS Foundation Trust; Faruque D Ghanchi, 
Bradford Teaching Hospitals NHS Trust; Geeta Menon, Frimley Park Hospital NHS 
Foundation Trust; Haralabos Eleftheriadis, Kings College Hospital NHS Foundation 
Trust; Hema Mistry, Warwick University; Jonathan Cook and William Sones, Centre 
for Statistics in Medicine, University of Oxford; Lindsay Prior, Centre for Public 
Health, Queens University, Belfast; Nachiketa Acharya, Sheffield Teaching Hospitals 
NHS Foundation Trust; Noemi Lois, Queen’s University and Royal Victoria Hospital 
Belfast H&SC Trust; Norman Waugh, Warwick University; Rachael Rice, Northern 
Ireland Clinical Trials Unit; Samia Fatum, John Radcliffe Hospital, Oxford University 
Hospitals NHS Foundation Trust; Sobha Sivaprasad, Moorfields Eye Hospital NHS 
Foundation Trust; Stephen Aldington and Peter H Scanlon, Gloucestershire Hospitals 
NHS Foundation Trust; Tariq M Aslam, Manchester Royal Eye Hospital, Central 
Manchester University Hospitals NHS Foundation Trust; Victor Chong, Royal Free 
Hospital NHS Foundation Trust, London. Clinical sites participating in recruitment: 
The Belfast Health and Social Care Trust, Belfast, Northern Ireland; Bradford 
Royal Infirmary, Bradford Teaching Hospitals NHS Foundation Trust; Bristol Eye 
Hospital, University Hospitals Bristol NHS Foundation Trust; Frimley Park Hospital 
NHS Foundation Trust; Gloucestershire Royal Hospital, Gloucestershire Hospitals 
NHSF Trust; James Cook University Hospital, South Tees Hospitals NHS Foundation 
Trust;Kings College Hospital NHS Foundation Trust; Manchester Royal Eye Hospital, 
Central Manchester University Hospitals NHS Foundation Trust; Moorfields Eye 
Hospital NHS Foundation Trust; John Radcliffe Hospital, Oxford University Hospitals 
NHS Foundation Trust; Queen Margaret Hospital, Fife; Sheffield Teaching Hospitals 
NHS Foundation Trust; Sunderland Eye Infirmary, City Hospitals Sunderland NHS 
Foundation Trust. EMERALD is currently recruiting. The first trial participant was 
recruited in October 2017. Trial Management Group: Professor Noemi Lois (Chief 
Investigator), Professor Augusto Azuara-Blanco, Mr Steve Aldington, Dr Danny 
McAuley, Mr Peter Scanlon, Mr Lindsay Prior, Mrs Clare Newall, Mrs Michelle 
McGaughey, Mrs Christine McNally, Miss Rachael Rice, Mr Andrew Jackson, Mr 
Jonathan Cook, Mr William Sones, Professor Norman Waugh, Dr Hema Mistry, 
Mr Mark Wilson, Mrs Nuala Hannaway, Mrs Catherine Campbell. Trial Steering 
Committee: Mr John Norrie (Chair); Mr David Owens; Mrs Florence Findlay-White; 
Mr Winfried Amoaku; Miss Yemisi Takwoingi. The roles and responsibilities of the 
TSC can be found in https://www. nihr. ac. uk/ funding- and- support/ documents/ 
funding- for- research- studies/ how- to- apply/ NETSCC_ Project_ Oversight_ Groups_ 
Guidance. pdf. A study Data and Ethics Monitoring Committee was not deemed 
 o
n
 4 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027795 on 28 June 2019. Downloaded from 
8 Lois N, et al. BMJ Open 2019;9:e027795. doi:10.1136/bmjopen-2018-027795
Open access 
necessary given the extremely low risk of this diagnostic study. Trial Sponsor: The 
Belfast Health and Social Care Trust, Belfast, Northern Ireland. Contact person: Ms 
Alison Murphy;  alison. murphy@ belfasttrust. hscni. net. 
Contributors NL conceived the study and drafted the protocol which was refined 
with input from JC, SA, NW, HM, WS, DMcA, TA, CB, VC, FG, PS, SS, DS, CS, LP 
and AA-B; JC and NL determined the sample size for the study and JC, WS and 
NL determined the statistical analysis plan. NW and HM planned the cost-
effectiveness evaluation. LP designed and planned the focus group discussions and 
will carry them out. CM, RR and AJ provided management coordination and data 
management to the study. NL, AS, CB, DS, FG, GM, HE, NA, SF, SS, SA, PHS, TA will 
recruit and evaluate patients for the study. All authors reviewed the manuscript, 
provided input to it and approved the final submitted version.
Funding This project was funded by the NIHR (Health Technology Assessment 
programme) (project number 13/142/04).
disclaimer The views expressed are those of the authors and not necessarily 
those of the NHS, the NIHR or the Department of Health and Social Care. Neither the 
Sponsor nor the Funder had any role on the study design; collection, management, 
analysis and interpretation of data; writing of this manuscript or in the decision to 
submit this manuscript for publication.
Competing interests NL, NW, AA-B, HM, DMcA, TA: none; CB: has been ad hoc 
advisor for Alcon, Bayer, Novartis, Alimera Sciences and Allergan; VC is a part-time 
employee of Boehringer Ingelheim International GmBH (BII), Germany; this study, 
however, is not being undertaken as part of the employment with BII and, thus, the 
content of this manuscript is not endorsed by BII. VC has also received speaker fees 
from Quantel Medical, France; SS has received research grants, travel feeds and 
attended advisory board meetings of Novartis, Bayer, Roche, Allergan, Heidelberg 
Engineering, Optos and Boehringer Ingelheim; DS acted as consultant to Alcon, 
attended advisory boards for Novartis and Bayer and received research funding 
from Bayer and Alcon. PS has attended Advisory Boards for Allergan, Roche, 
Boehringer and Bayer; his department has received Educational, Research or Audit 
Grants from Allergan, Novartis and Bayer. 
Patient consent for publication Not required.
Ethics approval Ethics approval was obtained from the Office for Research Ethics 
Committees Northern Ireland (ORECNI-17/NI/0124). 
Provenance and peer review Not commissioned; externally peer reviewed.
Author note Authorship policy: An author is considered someone who has made a 
substantive intellectual contribution to the study and the relevant report. 
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCEs
 1. Liew G, Michaelides M, Bunce C. A comparison of the causes 
of blindness certifications in England and Wales in working age 
adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open 
2014;4:e004015.
 2. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic 
retinopathy. Indian J Ophthalmol 2012;60:428–31.
 3. Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular 
oedema and related health and social care resource use in England. 
Br J Ophthalmol 2012;96:345–9.
 4. Yau JW, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease 
(META-EYE) Study Group. Global prevalence and major risk factors 
of diabetic retinopathy. Diabetes Care 2012;35:556–64.
 5. https://www. diabetes. org. uk.
 6. www. nice. org. uk/ guidance/ ta274.
 7. www. nice. org. uk/ guidance/ ta346.
 8. https://www. nice. org. uk/ guidance/ ta301.
 9. https://www. rcophth. ac. uk/ wp- content/ uploads/ 2014/ 12/ 2013- SCI- 
301- FINAL- DR- GUIDELINES- DEC- 2012- updated- July- 2013. pdf.
 10. Keenan TD, Johnston RL, Donachie PH, et al. United Kingdom 
National Ophthalmology Database Study: Diabetic Retinopathy; 
Report 1: prevalence of centre-involving diabetic macular oedema 
and other grades of maculopathy and retinopathy in hospital eye 
services. Eye 2013;27:1397–404.
 11. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating 
ranibizumab plus prompt or deferred laser or triamcinolone 
plus prompt laser for diabetic macular edema. Ophthalmology 
2010;117:1064–77.
 12. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE 
study: ranibizumab monotherapy or combined with laser versus 
laser monotherapy for diabetic macular edema. Ophthalmology 
2011;118:615–25.
 13. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic 
macular edema: results from 2 phase III randomized trials: RISE and 
RIDE. Ophthalmology 2012;119:789–801.
 14. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept 
for diabetic macular edema. Ophthalmology 2014;121:2247–54.
 15. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, 
or ranibizumab for diabetic macular edema. N Engl J Med 
2015;372:1193–203.
 16. Virgili G, Menchini F, Casazza G, et al. Optical coherence tomography 
(OCT) for detection of macular oedema in patients with diabetic 
retinopathy. Cochrane Database Syst Rev 2015;1:CD008081.
 17. Olson J, Sharp P, Goatman K, et al. Improving the economic value 
of photographic screening for optical coherence tomography-
detectable macular oedema: a prospective, multicentre, UK study. 
Health Technol Assess 2013;17:1–142.
 18. Knottnerus JA, Muris JW. Assessment of the accuracy of diagnostic 
tests: the cross-sectional study. J Clin Epidemiol 2003;56:1118–28.
 19. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised 
tool for the quality assessment of diagnostic accuracy studies. Ann 
Intern Med 2011;155:529–36.
 20. Obuchowski NA. Sample size calculations in studies of test 
accuracy. Stat Methods Med Res 1998;7:371–92.
 21. Silva PS, Cavallerano JD, Tolson AM, et al. Real-Time Ultrawide 
Field Image Evaluation of Retinopathy in a Diabetes Telemedicine 
Program. Diabetes Care 2015;38:1643–9.
 22. Piegorsch WW. Sample sizes for improved binomial confidence 
intervals. Comput Stat Data Anal 2004;46:309–16.
 23. Newcombe RG. Improved confidence intervals for the difference 
between binomial proportions based on paired data. Stat Med 
1998;17:2635–50.
 24. StataCorp. Stata Statistical Software: Release 14. College Station, 
TX: StataCorp LP, 2017.
 25. Kitzinger J. Qualitative research. Introducing focus groups. BMJ 
1995;311:299–302.
 26. Prior L, Analysis C, In PL, eds. The Oxford Handbook of Qualitative 
Research Methods: Oxford Library, 2014.
 o
n
 4 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027795 on 28 June 2019. Downloaded from 
